Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 As A Monotherapy Or In Combination With Pembrolizumab In Metastatic Breast Cancer At The 2021 San Antonio Breast Cancer Symposium®

Press/Media

PeriodDec 10 2021

Media coverage

33

Media coverage